<DOC>
	<DOCNO>NCT03050892</DOCNO>
	<brief_summary>Evaluate association donor soluble protein ST2 ( sST2 ) serum level 30-day recipient mortality order improve graft screening .</brief_summary>
	<brief_title>Impact Donor Recipient ST2 / IL-33 Pathway After Heart Transplantation</brief_title>
	<detailed_description>Soluble protein sST2 recently become prognostic biomarker context acute myocardial infarction chronic heart failure , recent study also show sST2 involve acute rejection cardiac graft recipient . Experimental study confirm ST2 / IL-33 pathway involve process lead cardiac transplant rejection animal . In particular , administration IL-33 would positive effect pre-clinical cardiac graft survival . No study look level ST2 / IL-33 donor , purpose might reflect condition transplant heart initial level Immune tolerance maybe predict risk subsequent dysfunction . In non-interventional study , several blood sample take donor organ procurement recipient prior graft , day 7 time myocardial biopsy ( approximately 16 myocardial biopsy first year ) . Serum level sST2 IL-33 determine accord ELISA method blood sample . Fifty consecutive couple donors/ recipient include study . This number subject calculated detect double donor sST2 level two recipient group 30-day mortality without mortality ( potency : 90 % , alpha risk : 0.05 , bilateral ) .</detailed_description>
	<criteria>Consenting recipient Consenting donor organ/tissue donation purpose scientific research Non consent recipient Non consent donor organ/tissue donation purpose scientific research Multiorgan transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>